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Abstract 
Clear cell Renal Cell (RCC) and Head and Neck Squamous Cell Carcinomas (HNSCC) are characterized by a 
pro-angiogenic/pro-inflammatory context. Despite conventional or targeted therapies, metastatic RCC and 
HNSCC remain incurable. Alternative treatments to reference therapies (sunitinib, a multi tyrosine kinase 
inhibitor for RCC or cisplatin for HNSCC) are urgently needed on relapse. Here, we described the relevance 
of targeting the ELR+CXCL cytokines receptors, CXCR1/2, for the treatment of these two cancer types. 
Methods: The relevance to patient treatment was evaluated by correlating the ELR+CXCL/CXCR1/2 levels to 
survival using online available data. We report herein the synthesis of new pharmacological inhibitors of 
CXCR1/2 with anti-proliferation/survival activity. The latter was evaluated with the XTT assay with leukemic, 
breast, RCC and HNSCC cell lines. Their relevance as an alternative treatment was tested on sunitinib- and 
cisplatin- resistant cells. The most efficient compound was then tested in a mouse model of RCC and HNSCC. 
Results: RCC and HNSCC expressed the highest amounts of CXCR1/2 of all cancers. High levels of 
ELR+CXCL cytokines (CXCL1, 2, 3, 5, 6, 7, 8) correlated to shorter survival. Among the 33 synthesized and 
tested molecules, compound C29 reduced ELR+CXCL/CXCR1/2-dependent proliferation and migration of 
endothelial cells. C29 exerted an anti-proliferation/survival activity on a panel of cancer cells including naive and 
resistant RCC and HNSCC cells. C29 reduced the growth of experimental RCC and HNSCC tumors by 
decreasing tumor cell proliferation, angiogenesis and ELR+/CXCL-mediated inflammation.  
Conclusion: Our study highlights the relevance of new CXCR1/2 inhibitors for the treatment of RCC or 
HNSCC as first-line treatment or at relapse on reference therapies. 
Key words: ELR+CXCL cytokines, Clear cell Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, 
CXCR1/2 inhibitor, angiogenesis. 
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Introduction 
Angiogenesis and inflammation are two closely 
interconnected hallmarks of cancer [1]. Inflammatory 
conditions induce the production of vascular 
endothelial growth factor (VEGF) by endothelial cells, 
tumor associated fibroblasts and tumor cells, resulting 
in angiogenesis. Hyper vascularization favors the 
transport of inflammatory cells and acute 
permeability of the neo-formed vessels facilitates the 
development of edema. Overall, inflammation 
induces angiogenesis, and angiogenesis enhances 
inflammation [2, 3]. 
Therefore, we aimed at developing new 
molecules to tackle concomitantly these two 
phenomena. In this study, we focused our attention 
on the pro-angiogenic and pro-inflammatory 
ELR+CXCL cytokines that include CXCL1–3, 5–8. 
These cytokines bind to two seven-transmembrane 
heptahelical G protein-coupled receptors, namely 
CXCR1 and CXCR2. Receptor stimulation activates 
several signaling pathways including the protein 
kinase C, phospholipase C, PI3K/AKT/mTOR, 
RAS/RAF/MEK/ERK and NFĸB pathways, leading 
to tumor cell survival, proliferation, and 
dissemination [4]. 
The leading member of the ELR+CXCL cytokines 
is CXCL8 (also called interleukin 8 or IL-8), which 
promotes angiogenesis, tumorigenesis, and metastasis 
[5]. The levels also correlated with tumor burden in 
several cancer types including prostate, ovarian, 
brain, and skin cancers [6]. CXCL1 is involved in 
esophageal, gastric, colorectal and skin cancer cell 
proliferation [7-10]. CXCL7 is a key player in the 
development of renal cell carcinoma (RCC), and in its 
response to sunitinib [11, 12]. Lastly, CXCL5 and 
CXCL8 correlated to head and neck squamous cell 
carcinoma (HNSCC) aggressiveness [13, 14]. 
CXCR1/2 are expressed by endothelial and 
inflammatory cells and are key players in 
angiogenesis and inflammation, especially in a 
hypoxic environment [15]. Moreover, the intra-tumor 
expression of CXCR2 correlated with relapse and poor 
prognosis of RCC patients with non-metastatic 
disease (M0) [16]. 
Thus, we hypothesized that small-sized organic 
antagonists of the ELR+CXCL that bind to CXCR1/2 
might exert a dual activity on both angiogenesis and 
inflammation. CXCR1/2 competitive and 
non-competitive inhibitors have been developed 
mainly for the treatment of pulmonary inflammatory 
disorders, and recently for advanced metastatic breast 
cancers [17]. 
We previously reported that the competitive 
CXCR1/2 inhibitor, SB225002, delays in vivo tumor 
growth and inflammation by antagonizing the 
signaling pathways induced by CXCL7. However, the 
anti-proliferative effect of SB225002 remains modest 
in vitro [12]. Therefore, the investigation of more 
potent analogues is of utmost interest. In line with 
these observations, two series of new and original N, 
N’-diaryl ureas and thioureas, featuring a 
nitro-benzothiazole moiety, were synthesized in an 
efficient way and evaluated as potential anti-cancer 
agents in two deadly cancers RCC and HNSCC. 
Among the 33 synthesized molecules, compound C29 
emerged as a promising lead, with interesting dual 
anti-angiogenic and anti-proliferative activities. 
Moreover, C29 reduced significantly the growth of 
experimental tumors in mice. Therefore, this study 
paves the way for future clinical trials targeting a 
pathway leading to three major hallmarks of cancers, 
i.e., tumor cell proliferation, angiogenesis and 
inflammation. 
Methods 
Chemistry  
The N, N’-diarylureas and thioureas (C1-C12) 
were conveniently synthesized according to a 
one-step procedure (Figure 1 and Figure S1), that 
should be used on a large scale for in vivo tests and 
pilot extrapolation. Briefly, the reaction consists in the 
nucleophilic attack of substituted anilines on mono- 
or di-substituted isocyanates and isothiocyanates, 
followed by spontaneous tautomerization. The 
expected N,N’-disubstituted ureas and thioureas have 
been obtained in good yields within a short reaction 
time by simple mixing of reactants at room 
temperature in the presence of an organic base 
(Figure 1, see also Supplementary Methods for 
details). 
Molecular simulation studies 
The RMN structure of CXCR1 (PDB ID : 2LNL) 
was retrieved from the Protein Data Bank (PDB) [18]. 
The RMN structure includes 10 conformations for 
CXCR1. Each conformation was considered 
separately, and the 10 resulting CXCR1 structures 
were prepared using MGL tools [19]. 
Three-dimensional structures of compound C29 were 
generated using iCon, the LigandScout v.4.3 
conformer generator [20] (defaults settings of the 
BEST option were used, except for the maximum 
number of conformations generated that was set to 50 
instead of 25). A total of 22 conformers of compound 
C29 was obtained. Protein – ligand docking of 
compound C29 into the CXCR1 structure was 
performed using AutoDock Vina v.1.1.2 [21]. As no 
information about the CXCR1 binding site of 
compound C29 was available, a blind docking 
approach was selected by docking compound C29 to 
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the whole surface of CXCR1, without restriction of the 
search space. Each of the 22 conformers of compound 
C29 were docked into each of the 10 CXCR1 
structures, resulting in 220 docking runs. For each 
run, 9 poses of compound C29 bound to CXCR1 were 
generated. The pose associated with the best score 
was considered for each run. 
Reagents and antibodies  
Sunitinib, SB225002 and danirixin were 
purchased from Selleckchem. Anti-HSP60 antibodies 
were purchased from Santa Cruz Biotechnology. 
Anti-AKT, anti-phospho-AKT, anti-ERK, 
anti-phospho-ERK antibodies were from Cell 
Signaling Technology. Methanol, ethyl acetate, 
diethyl ether and dichloromethane were purchased 
from Carlo Erba. Anhydrous DMF was purchased 
from Sigma Aldrich. All chemicals were purchased 
from Aldrich, Fisher or Alfa Aesar and used without 
further purification. 
Cell culture 
RCC4, 786-0 (786) and A498 (498) RCC cell lines, 
the MDA-MD-231 breast cancer cell line were 
purchased from the American Tissue Culture 
Collection. OCI-AML2, OCI-AML3, Molm13 and 
Molm14 acute myeloid cell lines (AML), and K562 
chronic myeloid cell line (CML), SKM1 
myelodysplastic cell line (MDS) were a kind gift from 
Dr. P. Auberger. Two human HNSCC cell lines, 
CAL33 and CAL27, were provided through a Material 
Transfer Agreement with the Oncopharmacology 
Laboratory, Centre Antoine Lacassagne (CAL) where 
they were initially isolated [22]. Primary RCC cells 
(CC, TF and 15S) have already been described and 
cultured in a medium specific for renal cells 
(PromoCell) [23].  
Immunoblotting 
Cells were lysed in buffer containing 3% SDS, 
10% glycerol and 0.825 mM Na2HPO4. 30 to 50 μg of 
proteins separated on 10% SDS-PAGE, transferred 
onto a PVDF membrane and then exposed to the 
appropriate antibodies. Proteins were visualized with 
the ECL system using horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse 
antibodies.  
 
 
Figure 1. CXCR1/CXCR2 inhibitors. Chemical structures of the synthesized N, N’-diarylureas and -thioureas, that have been evaluated as potential CXCR1 antagonists. 
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Migration assay 
CXCL7 or VEGFA-stimulated chemotaxis assays 
were monitored using modified Boyden chambers 
containing polycarbonate membranes (8-μm pores, 
Transwell; Corning, Sigma). Cells were seeded onto 
the upper side of the filters and chambers were placed 
on 24-well plates containing CXCL7 (50ng/ml) or 
VEGFA (50ng/ml). Cell migration was followed for 
24 h at 37°C in 5% CO2. Migratory cells on the lower 
membrane surface were fixed in 3% 
paraformaldehyde, stained with 0.1% crystal violet. 
Colony formation assay 
Cells (5000 cells per condition) were treated or 
not with C29, sunitinib. Colonies were detected after 
10 days of culture. Cells were then washed, fixed at 
room temperature for 20 min with 3% 
paraformaldehyde (PFA; Electron Microscopy 
Sciences) and colored with GIEMSA (Sigma). 
Caspase assays 
Caspase assays have already been described [24]. 
Briefly, the caspase 3 activity was assessed in 
quadruplicate using z-DEVD-AMC as substrate and 
the fluorescence were assessed. 
Flow cytometry 
CXCR2 measurement: After stimulation, cells 
were washed with PBS and stained with the 
CXCR2-PE antibody (Miltenyi) for 30 min at room 
temperature. Fluorescence was measured using the 
FL2 (PE) channels of a fluorescence-activated cell 
sorter apparatus (Calibur cytometer). 
Apoptosis analysis: After stimulation, cells were 
washed with ice-cold PBS and were stained with the 
annexin-V-fluo staining kit (Roche, Meylan, France) 
according to the manufacturer's procedure. 
Fluorescence was measured using the FL2 (AV) and 
FL3 (propidium iodide, PI) channels of a 
fluorescence-activated cell sorter apparatus (Calibur 
cytometer). 
Cell viability 
XTT 
Cells were incubated in a 96-well plate with 
different effectors for the times indicated in the figure 
legends. Fifty microliters of sodium 
3′-[1-phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-me
thoxy-6-nitro) benzene sulfonic acid hydrate (XTT) 
reagent was added to each well. The assay is based on 
the cleavage of the yellow tetrazolium salt XTT to 
form an orange formazan dye by metabolically active 
cells. This bio-reduction occurs in viable cells only and 
is related to NAD(P)H production through glycolysis. 
Therefore, the amount of formazan dye measured at 
490 nm directly correlated with the number of 
metabolically active cells reflecting cell proliferation 
and viability. Each assay was performed in 
quadruplicate.  
Cell number – ADAM 
For the experiments with C29, we confirmed all 
the results by evaluating the cell viability. Cell 
viability and cell death was assessed using the 
ADAM-MC apparatus (NanoEnTek, Guro-gu, Seoul, 
Korea) based on fluorescent propidium iodide 
staining according to the manufacturer's instructions.  
Selectivity index 
To determine the selectivity of the activity of the 
substances tested, the selectivity index (SI) was 
calculated according to the equation previously 
described [25] where SI = IC50 of a compound in a 
normal cell line/IC50 of the same compound in cancer 
cell line. The IC50 is the concentration required to kill 
50% of the cell population. 
Quantitative Real-Time PCR (qPCR) 
experiments 
One microgram of total RNA was used for the 
reverse transcription, using the QuantiTect Reverse 
Transcription kit (QIAGEN, Hilden, Germany), with 
blend of oligo (dT) and random primers to prime 
first-strand synthesis. SYBR master mix plus 
(Eurogentec) was used for qPCR. The mRNA level 
was normalized to 36B4 mRNA. The sequences of 
oligo nucleotides used in our experiments are 
describe in Table S1. 
In vitro stability assay of C29 
The in vitro stability was determined as followed: 
786-O cells were treated with 2.5 µM of compound 
C29 for the defined time, then lysed with methanol. 
The lysates were filtered and analyzed by 
UPLCMS/MS.  
Determination of the pharmacokinetic 
parameters 
The in vivo pharmacokinetic parameters were 
determined in CD-1 mice at a dose of 50 mg/kg after 
oral administration. The plasma samples (400 µL) 
were mixed with acetonitrile (1 mL) to precipitate the 
proteins and extract the compound. After mixing and 
sonication, proteins were precipitated by 
centrifugation and the supernatants were analyzed by 
UPLCMS/MS. 
Tumor xenograft experiments 
These studies were carried out in strict 
accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals. Our 
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experiments were approved by the ‘‘Comité National 
Institutionnel d’Ethique pour l’Animal de 
Laboratoire’’ (reference: PEA-255 and PEA-277). Cells 
were injected subcutaneously into the flank of 
5-week-old nude (nu/nu) female mice (Janvier). 
When the tumor reached 100 mm3, mice were treated. 
The tumor volume was determined with a caliper (v = 
L*l2*0.5).  
Ectopic model of RCC  
1- Seven million A498 cells were injected 
subcutaneously. Mice were treated five times a week 
for 4 weeks, by gavage with placebo (dextrose water 
vehicle) or C29 (50 mg/kg).  
2- Seven million 786-O cells were injected 
subcutaneously. Mice were treated trice a week by 
intraperitoneal injection with placebo (dextrose water 
vehicle), danirixin (200 µg), C29 (100 µg) or five times 
a week for four weeks, by gavage with sunitinib (50 
mg/kg). 
Ectopic model of HNSCC  
One million CAL33 were injected 
subcutaneously. Mice were treated five times a week 
for two weeks, by gavage with placebo (dextrose 
water vehicle), with danirixin (100 mg/kg) or C29 
(100 mg/kg) and once a week by intraperitoneal 
injection for cisplatin (4 mg/kg).  
Immunohistochemistry (IHC) 
Sections of formol-fixed and paraffin-embedded 
tumors were incubated with monoclonal anti-Ki67 
(clone MIB1, DAKO) or anti-CD31 (clone MEC 13.3, 
BD Pharmingen) antibodies. A biotinylated secondary 
antibody (DAKO) was applied and binding was 
detected with the substrate diaminobenzidine against 
a hematoxylin counterstain. 
Gene expression microarray analysis  
Normalized RNA sequencing (RNA-Seq) data 
produced by The Cancer Genome Atlas (TCGA) were 
downloaded from cBioportal (www.cbioportal.org, 
TCGA Provisional; RNA-Seq V2) [26, 27]. PFS was 
defined as the time between surgery and subsequent 
blood sampling and progression, or death from any 
cause, censoring live patients and progression free at 
last follow-up. OS was defined as the time from blood 
sample collection to the date of death from any cause, 
censoring those alive at last follow-up. The Kaplan 
Meier method was used to produce survival curves 
and significance was assessed using the log-rank test. 
Statistical analysis 
All data are expressed as the mean ± the 
standard error (SD). Statistical significance and p 
values were determined with the two-tailed Student’s 
t-test. One-way ANOVA was used for statistical 
comparisons. Data were analyzed with Prism 5.0b 
(GraphPad Software) with a one-way ANOVA with 
Bonferroni post hoc. 
Results 
The ELR+CXCL/CXCR pathway is linked to 
poor prognosis in RCC and HNSCC  
The levels of CXCR1/2 were obtained from the 
database of patients “The Cancer Genome Atlas 
(TCGA)”. Of the different tumors, HNSCC and RCC 
express the highest amounts of CXCR1 (Figure S2A). 
HNSCC is the second and RCC the seventh tumor 
type expressing the highest amount of CXCR2 (Figure 
S2B). The relevance of targeting the 
ELR+CXCL/CXCR1/2 axis was assessed by 
correlating the intra-tumor mRNA levels of 
ELR+CXCL cytokines to disease free/progression free 
(DFS/PFS) (Table 1A) and overall survival (OS) 
(Table 1B) of the RCC and HNSCC patients. High 
levels (> third quartile) of CXCL1-8 except CXCL7 
correlated with shorter DFS/PFS and OS for RCC 
patients whereas only CXCL1 and CXCL3 or CXCL1 
and CXCL8 correlated with shorter DFS/PFS and OS, 
respectively for HNSCC patients (Table 1A, B). RCC 
and HNSCC patients with multiple ELR+CXCL 
mRNA levels above the third quartile had the shortest 
OS (Figure S3A-C). OS was even shorter for RCC and 
HNSCC patients with ELR+CXCL and CXCR1/2 
mRNA levels above the third quartile (Figure S3B-D). 
These results strongly suggest that CXCR1/2 may 
represent a relevant target for the treatment of RCC 
and HNSCC. 
Selection of C29 as a lead compound 
A small focused chemical library of thirty-three 
new molecules was synthesized and evaluated for 
anti-proliferative activity against a panel of human 
tumor cell lines including breast, head and neck, 
hematologic and kidney tumor cells. The IC50 values 
for each compound were determined and compared 
to those of SB225002, a CXCR1/2 competitive 
inhibitor already tested for its effect on the growth of 
RCC tumor [12], and used as a reference compound; 
the results are listed in Table 2. 
N, N’-diaryureas and thioureas (C1-12) showed 
limited effect on malignant cells. However, two 
compounds sharing a common chlorobenzene ring 
(C9, C12) showed an IC50 in the 10 – 20 µmol/L range 
for solid tumors (breast and kidney), which was 
higher than the reference molecule SB225002. Other 
structural changes in the N, N’-disubstituted ureas, 
i.e., switching from a phenyl derivative to a 
benzimidazole or benzothiazole motif, resulted in a 
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higher IC50 (compounds C1-12 vs C13-33). However, 
the introduction of a benzoxazole ring (C18, C19) into 
the compounds did not give 
anti-proliferation/survival activity. Among the most 
potent derivatives, compounds C16, C25, C28, C29 
and C30, exhibited IC50 values below 20 µmol/L for 
several cancer cell lines. All these hits had a 
chlorophenyl ring, except compound C30. Among 
these five hits, only C16 contained an unsubstituted 
benzimidazole ring, the four other molecules were 
benzothiazoles substituted at position 6 with a methyl 
(C25), a nitro (C28, C29) or an ethoxy (C30). Lastly, in 
the specific case of kidney and head and neck tumor 
cells, C28 and C29 exerted a dramatic effect on cell 
proliferation/survival (A498: IC50 5 and 2.5 µmol/L 
respectively; 786-O: IC50 5 and 2 µmol/L respectively; 
CAL27: IC50 7 and 2.5 µmol/L respectively; CAL33: 
IC50 5 and 4 µmol/L respectively), underlying the 
potency of this class of molecules for treatment of 
RCC and HNSCC. 
Importantly, at a dose of 2.5 µmol/L, C29 did not 
affect the proliferation/survival of uveal melanoma 
cells (Mel202), which is consistent with a low level of 
expression of CXCR1/2 in this tumor type (Figure S2 
and S4). Based on this screening, we selected C29 as a 
lead compound for the following studies. It is worth 
nothing that C29 features a nitro-benzothiazole 
moiety that has not been reported before, attesting to 
the originality of this new class of bioactive 
compounds.  
 
Table 1. CXCL cytokines are associated with poor prognosis in RCC and in HSNCC. 446 RCC and 494 HNSCC patients 
were analyzed using the “The Cancer Genome Atlas (TCGA)”. The levels of CXCL1/2/3/5/6/7/8 mRNA correlated with 
disease/progression free survival (DSF/PFS) or with overall survival (OS). The third quartile value of CXCL expression was chosen as the 
reference. Statistical significance (p values) is indicated.  
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Table 2. Screening of the 33 newly synthesized N, N’-diarylureas and thioureas using different solid and hematological 
tumor cell lines. Values are reported as IC50 measured with the XTT assay (48 h). The results are expressed in μM, and all the IC50 
values given in this table showed a standard deviation of 10%. Results are represented as the mean of three independent experiments. 
 
 
C29 docking to CXCR1 
To address the specificity of C29 for CXCR1/2, 
we performed a blind docking approach. Several 
areas of CXCR1 were identified as possible C29 
binding sites. However, we noted that 14 out of the 15 
top poses ranked according to their AutoDock Vina 
scores, i.e. the 5% poses with the best scores, were all 
located at the same binding site. This binding site is a 
central buried pocket, the volume of which varies 
among the ten available conformations of CXCR1. The 
cytokine binding site contains Arg203, a residue 
previously identified by Alanine scanning 
experiments to be involved in the CXCR1/CXCL8 
interaction [28]. We thus propose a binding model, in 
which C29 is located in a buried central pocket of 
CXCR1 close to Arg203 (Figure 2). This finding 
supports the hypothesis that C29-CXCR1 binding will 
impede CXCL8 interaction with CXCR1. 
C29 inhibited ELR+CXCL-mediated 
proliferation and migration of endothelial cells  
CXCR1/2 are expressed on endothelial cells and 
participate in ELR+CXCL-mediated angiogenesis. We 
assessed the ability of C29 to inhibit CXCR1/2 in 
normal endothelial cells (HuVECs). CXCR1/2 are 
internalized upon stimulation, a process mainly 
involved in signal desensitization associated with G 
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protein coupled receptors and resulting in the transfer 
of receptors from the plasma membrane to the 
endosomal compartment [29]. Hence, modification of 
plasma membrane levels reflects, in part, stimulation. 
Following CXCL7 or CXCL8 stimulation in the 
presence of C29 (2.5 µmol/L), the CXCR1 or CXCR2 
levels at the plasma membrane were increased 
suggesting that C29 prevented CXCL7/8-dependent 
internalization of their receptors (Figure 3A-B). 
C29 decreased CXCL7-dependent but not 
VEGFA-dependent migration of HuVECs at the same 
concentration (2.5 µmol/L). Danirixin, a competitive 
inhibitor of CXCR2 and to a lesser extent of CXCR1 
[30], tested in phase II clinical trials for the treatment 
of Respiratory Syncytial Virus (RSV) infections, had 
no effect at this concentration (Figure 3C, Figure S5). 
This result suggests stronger efficacy of C29 
compared to danirixin. C29 also inhibited basal and 
CXCL5/CXCL7-dependent HuVECs viability (Figure 
3 D-E), which was consistent with inhibition of the 
activity of basal and CXCL5-dependent ERK/MAP 
Kinase signaling pathway (Figure 3F). Hence, C29 has 
a strong inhibitory effect on an alternative angiogenic 
pathway that compensates for the inhibition of the 
VEGF/VEGFR axis [31]. 
C29 is equally efficient on naive and resistant 
RCC and HNSCC cells 
The first-line treatments for RCC and HNSCC 
are respectively, sunitinib and cisplatin but relapse is 
ineluctably observed. Hence, our objectives were to; i) 
compare the efficacy of reference treatments to that of 
C29; ii) evaluate if C29 may be relevant at relapse as 
current standard of care. Dose responses and time 
courses were performed on naive cells and on 
sunitinib [32] and cisplatin-resistant cells to compare 
the C29 efficiency. C29 inhibited the viability of 
sensitive 786-O RCC cells as efficiently as sunitinib 
(786, Figure 4A-E, Figure S6A). The effect of C29 on 
cell viability was conserved in sunitinib-resistant 
786-O cells (786R, Figure 4B-F, Figure S6A). The effect 
of C29 on CAL27 HNSCC cell viability was greater 
than that of cisplatin (Figure 4C-G, Figure S6B), and 
the effect was equivalent for cisplatin-resistant CAL27 
cells (CAL27R, Figure 4D-H, Figure S6B). Compared 
to C29, the reference CXCR1/2 inhibitor SB225002 
had a modest effect on RCC and HNSCC cells (Figure 
S7). C29 inhibited the ERK/MAP Kinase and 
PI3K/AKT signaling pathways, two major pathways 
involved in cell proliferation, of naive and resistant 
RCC and HNSCC cells (Figure 5A-B). This result 
suggests that ELR+CXCL cytokines produced by RCC 
 
 
Figure 2. Blind docking study of C29 in CXCR1. Blind docking studies of the CXCR1 structure. Left panel: C13 (green), C14 (cyan), C26 (yellow), C28 (orange) and C29 
(magenta) best scored poses and C30 (white) second best scored pose are all located in a central buried pocket of the CXCR1 structure. Right panel: detailed view of the 
predicted interactions between C29 and CXCR1 residues with hydrogen bonds in yellow dashed lines and pi-stacking in green dashed lines (distances C29-H297: 2.8 Å, C29-Y77: 
3.1 Å, C29(CO)-N259: 2.9 Å, C29(NH)-N259: 2.9 Å). The CXCR1 residues surrounding the central buried pocket are visualized as a stick representation. The 3 CXCR1 
residues R199, R203 and D265, previously identified by Alanine scanning experiments to be involved in the CXCR1/CXCL8 interaction are represented as cyan sticks in both 
panels. 
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[31] and HNSCC [33] cells stimulate a 
CXCR1/2-dependent autocrine proliferation loop. 
C29 induced cell death in sensitive and resistant cells 
(Figure 5C-D). The apoptotic cell death induced by 
C29 was confirmed by an increase in the caspase 3 
activity in both cell types (Figure 5E-F).  
 
 
 
Figure 3. C29 inhibited the ERL+CXCL/CXCR1/2 axis in endothelial cells. (A) HuVEC were stimulated with 25 ng/ml CXCL7 during 1 h. Membrane-associated 
CXCR1 protein levels were quantified by flow cytometry. (B) HuVEC were stimulated with 25 ng/ml CXCL8 during 1 h. Membrane-associated CXCR2 protein levels were 
quantified by flow cytometry. (C) CXCL7 (50 ng/ml) or VEGFA (50 ng/ml)-dependent HuVEC migration was analyzed using Boyden chamber assays in the presence/absence of 
C29 (1 or 2.5 µM) or danirixin (2.5 µM). (D) HuVEC were grown in the presence of different concentrations of C29 for 48 h. Cell viability was measured with the XTT assay. 
(E) HuVEC were incubated with 100 ng/ml CXCL5 or CXCL7, in the presence of the indicated concentrations of C29 for 48 h. Cell viability was measured with the XTT assay. 
(F) HuVEC were pre-treated with 5 µM C29 for 1 h then stimulated with 50 ng/ml CXCL5 for 10 min. p-ERK levels were analyzed by immunoblotting. ERK and HSP60 served 
as loading controls. Results are represented as the mean of three independent experiments ± SEM. Statistical significance was determined using an unpaired Student’s t-test: 
*P<0.05; **P<0.01; ***P<0.001. 
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Figure 4. C29 decreased the viability of sensitive and resistant RCC and HNSCC cells. (A) and (B) RCC naive (786, A), and sunitinib-resistant (786R, B) 786-O cells, 
were treated with C29 or sunitinib (1 to 10 µM) for 48 h. Cell viability was measured with the XTT assay. (C) and (D), HNSCC naive (CAL27, C), and cisplatin-resistant 
(CAL27R, D) CAL27 cells, were treated with C29 or cisplatin (1 to 10 µM) for 48 h. Cell viability was measured with XTT assays. (E) and (F), 786 (E), 786R (F), were treated 
with 2.5 µM C29 or 2.5 µM sunitinib for 24 to 96 h. Cell viability was measured with the XTT assay. (G) and (H), CAL27 (G), CAL27R (H), were treated with 2.5 µM C29 or 
2.5 µM cisplatin for 24 h to 96 h. Cell viability was measured with the XTT assay. Results are represented as the mean of three independent experiments ± SEM. Statistical 
significance was determined using an unpaired Student’s t-test: *P<0.05; **P<0.01; ***P<0.001. 
 
To further explore the effect of C29 we compared 
its activity on tumor kidney cells to that on primary 
normal cells [34]. C29 significantly decreased the 
proliferation of primary kidney tumor cells (CC, TF, 
Figure S8A-B) but had no effect on primary normal 
kidney cells (15S), even when C29 was used at a 
higher concentration (5 µmol/L). FACS analysis 
detected apoptotic markers in TF and CC cells in the 
presence of C29 at 1 µmol/L, which was not the case 
for normal cells (15S, Figure S8C). The results with 
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primary cells were similar to those described above 
for kidney cell lines. 
We then calculated the selectivity index (SI) to 
evaluate the selectivity to the targets. The normal 
primary kidney cells (15S) served as the reference 
value. The SI was superior to that of Mel202 for all 
tumor cells (Table 3), which is in favor of a specific 
effect on CXCR1/2 receptors. 
C29 inhibited the growth of experimental RCC 
and HNSCC 
To be confident about using C29 for in vivo 
experiments in mice, we first tested its stability by 
performing UPLC/HRMS analyzes on the 786-O cells. 
No degradation of C29 was observed after a 24 
h-treatment at room temperature (Figure 6A), 
 
 
Figure 5. C29 inhibited signaling pathways associated with cell proliferation and survival, and induced apoptotic cell death of sensitive and resistant RCC 
and HNSCC cells. (A) and (B), 786 and 786R cells (C), and CAL27 and CAL27R (D) were treated with 2.5 µM C29 for 1 h to 48 h. p-ERK and p-AKT levels were determined 
by immunoblotting. ERK and AKT served as loading controls. (C) and (D), 786 and 786R cells (C), and CAL27 and CAL27R (D) were treated with 2.5µM C29 for 48 h. 
Histograms show both annexin-V+/PI− cells (white bars) and annexin-V+/PI+ cells (black bars). (E) and (F), 786 and 786R cells (E), and CAL27 and CAL27R (F) were treated with 
2.5 and 5 µM C29, or with 2.5 µM sunitinib (suni) or with 3 µM cisplatin (cis) for 48 h. The caspase 3 activity was evaluated using 0.2 mM Ac-DEVD-AMC as substrate. Results 
expressed as arbitrary units (A.U.) are means ± standard deviation of three independent experiments. Statistical significance was determined using an unpaired Student’s t-test: 
*P<0.05; **P<0.01; ***P<0.001. 
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attesting to its high stability in cellulo. C29 was then 
formulated at 7.6 mg/mL and administrated by oral 
gavage at 50 mg/kg. C29 exhibited a half-life of 190 
min, combined with a CMAX of 0.9 µg/ml at 30 min 
(Figure 6B). Global exposure remained high and the 
AUC was close to 85000 min.ng/m. These results 
prompted us to evaluate C29 on the growth of 
experimental tumors in mice. 
C29 slowed-down the growth of experimental 
RCC or HNSCC with a decrease of more than 65% of 
the tumor volume at the end of the experiment 
(Figure 7A-8A). This result correlated with the 
decrease in the tumor weight of 40 or 65% for RCC 
and HNSCC, respectively (Figure 7B-8B). Moreover, 
we did not observe any weight loss of the animals in 
the treated group, which suggests that this molecule 
did not exert acute toxicity (Figure 7C-8C). C29 
decreased the proliferation marker Ki-67 (Figure 
7D-8D) and inhibited PI3K/AKT but not the ERK 
pathway in experimental RCC (Figure 7E-F) and both 
pathways in experimental HNSCC (Fig. 8E-F). The 
mRNA level of murine CD31, a relevant marker of 
blood vessels, was decreased for both tumor types 
(Figure 7G-8G). The mRNA levels of ERL+CXCL 
cytokines (CXCL5/7/8), but not of VEGFA, were 
significantly decreased by C29 in experimental RCC 
(Figure 7H-K). Only CXCL5 was decreased in 
experimental HNSCC (Figure 8H-K). These results 
were consistent with the decrease in blood vessels 
visualized by the down-regulation of CD31 levels on 
IHC (Figure 7G- 8G).  
The concentration in blood (CMAX) of C29 once 
administered by oral gavage was 2.6 µmol/L 
(comparable to the in vitro IC50), which means that a 
small amount of the drug crossed the gastric barrier. 
Therefore, we tested the efficacy of C29 administered 
by intra-peritoneal injection. Three injections per 
week of 100 µg C29 was as efficient as a dose of 50 
mg/kg administered by oral gavage (Figure S9A-B). 
An equivalent efficacy was obtained with danirixin at 
200 µg three times a week or sunitinib 50 mg/kg by 
oral gavage five times a week (Figure S9C-D). C29 
administered by oral gavage at a dose of 100 mg/kg 
five times a week was more efficient than danirixin, at 
the same dose, or than the reference treatment with 
cisplatin on experimental HNSCC (Figure S9E-F). C29 
treatment (100mg/kg by oral gavage five times a 
week for three weeks) did not induce hematological, 
renal or hepatic toxicity (Figure S10A-D). These 
results strongly suggest that C29 may represent a 
relevant therapeutic tool for RCC and HNSCC. 
 
Table 3. Comparison of IC50 and the selectivity index for the different cell lines 
 
 
 
Figure 6. Determination of the in cellulo (A) stability and in vivo pharmacokinetic parameters (B) of compound C29. (A) 786-O cells were treated with 2.5 µM 
of C29 for 24 h at room temperature, then cells were lyzed with methanol. UPLCMS/MS analyses highlighted the absence of degradation of the compound at this time point. (B) 
C29 was formulated at 7.6 mg/mL and administrated by oral gavage at 50 mg/kg in CD-1 mice. The plasma samples (400 µL) were mixed with acetonitrile (1 mL) and sonicated. 
Proteins were precipitated by centrifugation and the supernatants were analyzed by UPLCMS/MS. 
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Figure 7. In vivo mouse RCC xenograft experiments. Seven million A498 cells were injected subcutaneously into the flank of nude mice. When the tumor reached 100 
mm3, mice were treated five times a week for four weeks by gavage with placebo (dextrose water vehicle) or C29 (50 mg/kg). (A) The tumor volume was measured twice weekly. 
The results are presented as the means ± sd. (B) Tumor weights at the end of the experiment. (C) Weights of the animals at the end of the experiment. (D) Human Ki67 
expression in untreated and treated mice. The number of proliferative cells was determined by calculating the ratio of colocalized 4,6 diamidino-2-phenylindole 
(DAPI)/Ki67-positive cells with respect to the total cell number. (E) and (F) The levels of pERK, ERK, pAKT and AKT in tumor lysates were determined by immunoblotting. The 
graphs represent the ratio of pERK (E) or pAKT (F) to non-phosphorylated ERK or AKT. (G) Blood vessels were visualized by IHC for CD31. (H-K) The levels of human VEGFA, 
CXCL5, CXCL7 and CXCL8 mRNA in tumors were evaluated by qPCR. Statistical significance was determined using an unpaired Student’s t-test: *P<0.05; **P<0.01; ***P<0.001. 
 
Figure 8. In vivo mouse HNSCC xenograft experiments. One million CAL33 cells were injected subcutaneously into the flank of nude mice. When the tumor reached 100 
mm3, mice were treated five times a week for two weeks by gavage with placebo (dextrose water vehicle) or C29 (100 mg/kg). (A) The tumor volumes are presented as the 
means ± sd. (B) Tumor weights at the end of the experiment. (C) Weights of the animals at the end of the experiment. (D) Human Ki67 expression in untreated and treated mice. 
The number of proliferative cells was determined by calculating the ratio of colocalized 4,6 diamidino-2-phenylindole (DAPI)/Ki67-positive cells with respect to the total cell 
number. (E) and (F) The levels of pERK, ERK, pAKT and AKT in tumor lysates were determined by immunoblotting. The graphs represent the ratio of pERK (E) or pAKT (F) 
to non-phosphorylated ERK or AKT. (G) Blood vessels were visualized by IHC for CD31. (H-K) The level of human VEGFA, CXCL5, CXCL7 and CXCL8 mRNA in tumors were 
evaluated by qPCR. Statistical significance was determined using an unpaired Student’s t-test: *P<0.05; **P<0.01; ***P<0.001. 
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Discussion 
The therapeutic options for RCC and HNSCC at 
a metastatic stage are anti-angiogenic drugs or 
immunotherapy, alone or in combination [35, 36], and 
a combination of radio/chemotherapy, respectively 
[37]. Despite an increase in time to progression, the 
patients ineluctably relapse within a few months [38]. 
We have already demonstrated that the CXCL/CXCR 
axis is involved in relapse of RCC patients [12, 33]. We 
report herein the identification and biological 
characterization of a new series of CXCR1/2 
inhibitors with significant anti-cancer effects. The lead 
compound of this series, C29, inhibited tumor cell 
viability and angiogenesis, two major hallmarks of 
aggressive cancers [39]. This study highlighted the 
possibility of targeting CXCL/CXCR crosstalk using a 
potent CXCR1/2 inhibitor, as a relevant therapeutic 
option to treat incurable RCC and HNSCC. C29 
showed higher efficacy in two independent tumor 
types as compared to the older generation of 
competitive inhibitors SB225002 or danirixin. 
Targeting the CXCL/CXCR signaling pathway 
induced; i) inhibition of proliferation of tumor and 
endothelial cells, ii) tumor cell death, and iii) 
inhibition of tumor vascularization. A high expression 
level of ELR+CXCL cytokines and their receptors in 
RCC and HNSCC suggested that CXCR inhibitors 
may be considered as relevant first-line treatment. 
Since C29 may represent an option on relapse when 
on reference therapies early phase clinical trials can be 
rapidly performed. The rationale in the case of 
therapeutic failure is sound for both tumors. 
We observed that ELR+CXCL cytokines were 
induced in response to the reference anti-angiogenic 
treatment sunitinib in RCC [24] and in response to 
radiotherapy in HNSCC [26]. These results represent 
a relevant rationale to administer CXCR inhibitors on 
relapse. 
RCC and HNSCC are inflamed tumors and 
therefore eligible for immunotherapy. Indeed, 
immunotherapy improved the outcome of RCC [35, 
40] and HNSCC [41]. However, only 30% of patients 
benefit from these treatments [35, 42]. The presence of 
myeloid-derived suppressor cell (MDSC) partly 
explains the limited effect of immunotherapies in 
some patients [31, 33]. A correlation between the 
intra-tumor expression of CXCL5, CXCL8 and IL1β, 
and the presence of MDSC, creating an 
immuno-suppressive environment, has been recently 
highlighted in RCC [43]. Moreover, we demonstrated 
the IL1β controls the expression of CXCL7, one of the 
main CXCL cytokines involved in RCC 
aggressiveness [12]. Thus, by decreasing 
CXCR-expressing MDSC, C29 might reactivate the 
anti-tumor immune response. In addition to its 
anti-viability and anti-angiogenic effects, C29 may 
serve indirectly as an immune check point inhibitor 
and can also sensitize tumors to immunotherapy by 
decreasing the level of cytokines favoring anergia. 
Therefore, C29 has the ability to target four hallmarks 
of cancers; proliferation of tumor cells, tumor 
angiogenesis, chronic inflammation and 
immune-tolerance. Our efforts are currently directed 
towards the validation of this hypothesis, and the 
results will be reported in due course.  
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